TFEB downregulation or deficiency can obviously affect the cellular phenotype in a physiologically relevant manner in settings including atherosclerosis [26], nonalcoholic fatty liver disease [27], cancer [28] and neurodegeneration [29]. This evidence concerns the gene TFEB and cancer.